James E. Berg

James E.
Berg has served as Vice President, Clinical and Regulatory Affairs, since March 1997.
Mr. Berg led the team responsible for the clinical trials program for docosanol 10% cream and had the responsibility for working with the FDA and other regulatory agencies that led to the approvals of the product in the U.S., Canada and Sweden and other countries.
Mr. Berg is also responsible for managing the clinical trials of Neurodex for the treatment of PBA and neuropathic pain and for the Company's lead compound for the treatment of allergy and asthma.
From August 1992 to March 1997, Mr. Berg was Director of Clinical Affairs and Product Development at the Company.
Earlier in his career, Mr. Berg held various sales and management positions at QUIDEL Corporation, San Diego, California, and at Krupp Bilstein Corporation of America, Inc., San Diego, California.
Mr. Berg received his B.A.
degree from the University of Wisconsin in 1973.